169 related articles for article (PubMed ID: 31688243)
1. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
3. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
4. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
5. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity.
Fujii H; Yoshida M; Gong ZX; Matsumoto T; Hamano Y; Fukunaga M; Hruban RH; Gabrielson E; Shirai T
Cancer Res; 2000 Jan; 60(1):114-20. PubMed ID: 10646862
[TBL] [Abstract][Full Text] [Related]
6. Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas.
Costa MJ; Morris RJ; Wilson R; Judd R
Hum Pathol; 1992 Jul; 23(7):787-97. PubMed ID: 1612579
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube.
See SHC; Behdad A; Maniar KP; Blanco LZ
Int J Surg Pathol; 2019 Aug; 27(5):574-579. PubMed ID: 30913944
[No Abstract] [Full Text] [Related]
8. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.
Rottmann D; Snir OL; Wu X; Wong S; Hui P; Santin AD; Buza N
Mod Pathol; 2020 Jan; 33(1):118-127. PubMed ID: 31477811
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations.
McCluggage WG; Apellaniz-Ruiz M; Chong AL; Hanley KZ; Velázquez Vega JE; McVeigh TP; Foulkes WD
Am J Surg Pathol; 2020 Jun; 44(6):738-747. PubMed ID: 31990691
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
12. Ovarian sex cord-stromal tumors in patients with probable or confirmed germline DICER1 mutations.
Oost EE; Charles A; Choong CS; Leung YC; Salfinger S; Sonnendecker H; Tan J; Townshend S; Witkowski L; Foulkes WD; Stewart CJ
Int J Gynecol Pathol; 2015 May; 34(3):266-74. PubMed ID: 25844550
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
Schipf A; Mayr D; Kirchner T; Diebold J
Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses.
Harms PW; Fullen DR; Patel RM; Chang D; Shalin SC; Ma L; Wood B; Beer TW; Siddiqui J; Carskadon S; Wang M; Palanisamy N; Fisher GJ; Andea A
Hum Pathol; 2015 May; 46(5):690-7. PubMed ID: 25704628
[TBL] [Abstract][Full Text] [Related]
15. Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation.
Gilcrease MZ; Delgado R; Albores-Saavedra J
Arch Pathol Lab Med; 1998 Oct; 122(10):907-11. PubMed ID: 9786352
[TBL] [Abstract][Full Text] [Related]
16. DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors.
Karnezis AN; Wang Y; Keul J; Tessier-Cloutier B; Magrill J; Kommoss S; Senz J; Yang W; Proctor L; Schmidt D; Clement PB; Gilks CB; Huntsman DG; Kommoss F
Am J Surg Pathol; 2019 May; 43(5):628-638. PubMed ID: 30986800
[TBL] [Abstract][Full Text] [Related]
17. DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects.
Kato N; Kusumi T; Kamataki A; Tsunoda R; Fukase M; Kurose A
Hum Pathol; 2017 Jan; 59():41-47. PubMed ID: 27664536
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
19. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations.
Croce S; de Kock L; Boshari T; Hostein I; Velasco V; Foulkes WD; McCluggage WG
Int J Gynecol Pathol; 2016 Jul; 35(4):301-8. PubMed ID: 26598979
[TBL] [Abstract][Full Text] [Related]
20. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
Amatya VJ; Takeshima Y; Kaneko M; Inai K
Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
